AI-driven decision support can ease oncologists’ workloads and streamline care without reducing autonomy.
The FDA has granted approval to adjuvant cemiplimab treatment for patients with high-risk cutaneous squamous cell carcinoma ...
A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication ...
Panelists discuss how the subcutaneous nivolumab data demonstrate reassuring safety with minimal grade 3/4 events, how ...
Supportive oncology interventions provide a comprehensive approach to oncology, addressing patients’ needs holistically, which start with understanding a patient’s baseline ne ...
The use of ctDNA after surgery can provide guidance to patients who may be receiving input on treatment decisions from every ...
C, OCN, discusses planning beyond first-line CDK4/6 inhibitors and supportive care strategies for patients with HR+/HER2– ...
Subcutaneous daratumumab is well tolerated, but ongoing immune monitoring is key to managing infection risk in patients with ...
An LED-based intraoral device for photobiomodulation therapy was safe and reduced severe oral mucositis in patients with head ...
The REMS program for vandetanib in the treatment of patients with medullary thyroid cancer has been removed by the FDA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results